ABSTRACT
OBJECTIVES: Parental exposure to pesticides and the risk of leukemia in offspring were examined in a population-based case-control study in Costa Rica. METHODS: All cases of childhood leukemia (N=334), in 1995-2000, were identified at the Cancer Registry and the Children's Hospital. Population controls (N=579) were drawn from the National Birth Registry. Interviews of parents were conducted using conventional and icon-based calendar forms. An exposure model was constructed for 25 pesticides in five time periods. RESULTS: Mothers' exposures to any pesticides during the year before conception and during the first and second trimesters were associated with the risk [odds ratio (OR) 2.4, 95% confidence interval (95% CI) 1.0-5.9; OR 22, 95% CI 2.8-171.5; OR 4.5, 95% CI 1.4-14.7, respectively] and during anytime (OR 2.2, 95% CI 1.0-4.8). An association was found for fathers' exposures to any pesticides during the second trimester (OR 1.5, 95% CI 1.0-2.3). An increased risk with respect to organophosphates was found for mothers during the first trimester (OR 3.5, 95% CI 1.0-12.2) and for fathers during the year before conception and the first trimester (OR 1.5, 95% CI 1.0-2.2 and OR 1.6, 95% CI 1.0-2.6, respectively), and benzimidazoles during the first, second, and third trimesters of pregnancy (OR 2.2, 95% CI 1.0-4.4; OR 2.2, 95% CI 1.0-5.0; OR 2.2, 95% CI 1.0-5.2, respectively). There was a suggestion of an exposure-response gradient for fathers as regards picloram, benomyl, and paraquat. Age at diagnosis was positively associated with fathers' exposures and inversely associated with mothers' exposures. CONCLUSIONS: The results suggest that parental exposure to certain pesticides may increase the risk of leukemia in offspring.
Subject(s)
Leukemia/etiology , Occupational Exposure , Parents , Pesticides/adverse effects , Adolescent , Child , Child, Preschool , Costa Rica/epidemiology , Female , Humans , Infant , Infant, Newborn , Interviews as Topic , Leukemia/epidemiology , Male , Odds Ratio , Registries , Risk AssessmentABSTRACT
OBJECTIVE: To assess the clinical prognosis of patients with coronary artery diseases undergoing percutaneous revascularization with drug-eluting stent implantation in the proximal left anterior descending coronary artery. METHODS: One hundred and seventy consecutive patients with mean age of 65 years, 49 of them females (29%), undergoing implantation of at least one drug-eluting stent in our medical center. The total number of drug-eluting stents implanted was 189, of which 115 (61%) were sirolimus-eluting (CYPHER) and 74 (39%) were paclitaxel-eluting stents (TAXUS). In 100 (60%) of the cases, multivessel coronary artery disease was present. In 61 (36%) patients another coronary artery segment was treated in addition to the proximal left anterior descending coronary artery. The mean clinical follow-up period was 11 +/- 5 months, and angiographic controls were performed between 6 and 9 months. The final endpoint was a composite of death, acute myocardial infarction and need for reintervention on the anterior descending. The secondary endpoint included the occurrence of restenosis, need for reintervention on the proximal segment of the left anterior descending and stent thrombosis. RESULTS: The procedure achieved immediate angiographic success in all patients. Two deaths, two acute myocardial infarctions, and two percutaneous coronary reinterventions due to stent thrombosis were recorded during in-hospital stay. At the sixth month of follow-up, an additional cardiac death and three myocardial infarctions were observed; three repeat revascularization procedures were required. Up to the end of the follow-up, three additional deaths, three myocardial infarctions and eight revascularization procedures of the anterior descending, two of them surgical, were verified. Survival free from major adverse cardiac events was 91%. Cardiac mortality was 3%. Binary restenosis in the proximal segment of the left anterior descending coronary artery was 4.1%. Target vessel revascularization-free survival was 94%. No cases of late stent thrombosis were observed. CONCLUSION: Percutaneous revascularization of the proximal left anterior descending coronary artery with implantation of drug-eluting stents is a safe and very efficient therapeutic strategy in the short and long terms.
Subject(s)
Angioplasty, Balloon, Coronary/methods , Coronary Stenosis/therapy , Paclitaxel/administration & dosage , Sirolimus/administration & dosage , Stents , Aged , Aged, 80 and over , Coronary Angiography , Coronary Restenosis/diagnostic imaging , Coronary Restenosis/prevention & control , Coronary Stenosis/mortality , Coronary Stenosis/surgery , Drug Implants/therapeutic use , Female , Follow-Up Studies , Humans , Male , Middle Aged , Myocardial Revascularization/methods , Prognosis , Survival Analysis , Treatment OutcomeABSTRACT
OBJETIVO: Avaliar o prognóstico clínico dos doentes coronários submetidos a revascularização percutânea com implantação de stents revestidos com fármacos na descendente anterior proximal. MÉTODOS: Cento e setenta doentes consecutivos, com idade média de 65 anos, 49 (29 por cento) mulheres, receberam implante de pelo menos um stent revestido com fármaco, no nosso centro. O número total de stents revestidos com fármaco implantados foi 189, dos quais 115 (61 por cento) de sirolimus (CYPHER®) e 74 (39 por cento) de paclitaxel (TAXUS®). Em 100 (60 por cento) dos casos, estava presente doença coronário multivaso. Em 61 (36 por cento) dos doentes tratou-se outro segmento coronário para além da descendente anterior proximal. Efetuou-se um seguimento clínico durante um tempo médio de 11 ± 5 meses e controle angiográfico entre os seis e os nove meses. Obteve-se um endpoint final composto por morte, infarto agudo do miocárdio e pela necessidade de reintervenção sobre a descendente anterior. Analisou-se secundariamente a ocorrência de reestenose, a necessidade de reintervenção sobre o segmento proximal da descendente anterior e a trombose de stent. RESULTADOS: O procedimento teve êxito angiográfico imediato em todos os doentes. Registraram-se duas mortes, dois infartos agudos do miocárdio, e duas reintervenções coronárias percutâneas por trombose de stent no período intra-hospitalar. Aos seis meses de seguimento, observou-se mais uma morte cardíaca e identificaram-se três infartos do miocárdio; houve necessidade de três novos procedimentos de revascularização. Até ao final do seguimento, verificaram-se mais três mortes, três infartos do miocárdio e oito revascularizações da descendente anterior, duas delas por cirurgia. A sobrevivência livre de eventos cardíacos adversos maior foi de 91 por cento. A mortalidade cardíaca foi de 3 por cento. A reestenose binária no segmento proximal da descendente anterior foi de 4,1 por cento. A sobrevivência livre...
OBJECTIVE: To assess the clinical prognosis of patients with coronary artery diseases undergoing percutaneous revascularization with drug-eluting stent implantation in the proximal left anterior descending coronary artery. METHODS: One hundred and seventy consecutive patients with mean age of 65 years, 49 of them females (29 percent), undergoing implantation of at least one drug-eluting stent in our medical center. The total number of drug-eluting stents implanted was 189, of which 115 (61 percent) were sirolimus-eluting (CYPHER TM) and 74 (39 percent) were paclitaxel-eluting stents (TAXUS TM). In 100 (60 percent) of the cases, multivessel coronary artery disease was present. In 61 (36 percent) patients another coronary artery segment was treated in addition to the proximal left anterior descending coronary artery. The mean clinical follow-up period was 11 ± 5 months, and angiographic controls were performed between 6 and 9 months. The final endpoint was a composite of death, acute myocardial infarction and need for reintervention on the anterior descending. The secondary endpoint included the occurrence of restenosis, need for reintervention on the proximal segment of the left anterior descending and stent thrombosis. RESULTS: The procedure achieved immediate angiographic success in all patients. Two deaths, two acute myocardial infarctions, and two percutaneous coronary reinterventions due to stent thrombosis were recorded during in-hospital stay. At the sixth month of follow-up, an additional cardiac death and three myocardial infarctions were observed; three repeat revascularization procedures were required. Up to the end of the follow-up, three additional deaths, three myocardial infarctions and eight revascularization procedures of the anterior descending, two of them surgical, were verified. Survival free from major adverse cardiac events was 91 percent. Cardiac mortality was 3 percent. Binary restenosis in the proximal segment...
Subject(s)
Humans , Male , Female , Middle Aged , Aged, 80 and over , Angioplasty, Balloon, Coronary/methods , Coronary Stenosis/therapy , Paclitaxel/administration & dosage , Stents , Sirolimus/administration & dosage , Coronary Angiography , Coronary Restenosis/prevention & control , Coronary Restenosis , Coronary Stenosis/mortality , Coronary Stenosis/surgery , Follow-Up Studies , Myocardial Revascularization/methods , Prognosis , Survival Analysis , Treatment OutcomeABSTRACT
The nematocide 1,2-dibromo-3-chloropropane (DBCP), widely used in Costa Rica during the late 1960s and 1970s, causes sterility in men and is a possible carcinogen. Mortality among a cohort of Costa Rican banana plantation workers was investigated. The cohort included 40,959 individuals who worked on banana plantations between 1972 and 1979. Employment records were linked with the Costa Rican Mortality Registry to determine outcomes through 1999. Standardized mortality ratios (SMRs) were calculated for all causes of death. Poisson regression was also used to calculate mortality risk estimates by duration of employment, but provided no additional insight. All-causes SMRs were 0.77 for men (95% CI 0.75-0.80) and 0.90 for women (95% CI 0.80-1.02) relative to national mortality rates. Mortality from septicemia was significantly higher than expected. Nonsignificant increases in mortality were also observed for testicular cancer, penile cancer, Hodgkin's disease, and Parkinson's disease in men, and for cervical cancer and lung cancer in women.